Journals

I subscribe to a number of journals.

New England Journal of Medicine

Testing in a Pandemic — Improving Access, Coordination, and Prioritization
New England Journal of Medicine, Volume 384, Issue 3, Page 197-199, January 2021.
>> Read more

Roman Catholic Diocese of Brooklyn v. Cuomo — The Supreme Court and Pandemic Controls
New England Journal of Medicine, Volume 384, Issue 3, Page 199-201, January 2021.
>> Read more

Incarceration and Social Death — Restoring Humanity in the Clinical Encounter
New England Journal of Medicine, Volume 384, Issue 3, Page 201-203, January 2021.
>> Read more

Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
New England Journal of Medicine, Volume 384, Issue 3, Page 205-215, January 2021.
>> Read more

Heart

Heartbeat: the COVID-19 pandemic and the future of cardiology
The COVID-19 pandemic created challenges which exposed inefficiencies, inequities, lack of resiliency and outdated models for the delivery of cardiovascular care around the globe. At the same time, the response to this crisis has allowed rapid transformation of our systems of care, including widespread use of digital interfaces, streamlining of care pathways and improved integration of patient-centric clinical services. In the hope of ensuring that this positive transformation is carried forward the British Cardiovascular Society (BCS) has outlined these changes and identified additional areas that require improvement as summarised in a short article in this issue of Heart1 with the full report available on the BCS website.2 As they conclude: ‘cardiology, like other specialties, needs to assimilate and act on the lessons learnt during the pandemic. This will require a restructuring of the way that we all work and deliver clinical services.’ The insights summarised...
>> Read more

Biomarkers for detection of a thrombus in the left atrial appendage: the search for the grail?
Patients with atrial fibrillation (AF) undergoing either pulmonary vein isolation (PVI) or direct current cardioversion (DCCV) most commonly undergo transoesophageal echocardiography (TOE) for definite exclusion of a thrombus in the left atrial appendage (LAA).1 As TOE as a semi-invasive procedure is not without risk to the patient and during the current times with a still ongoing SARS-Cov-2 pandemic for the clinician, a definite exclusion of LAA thrombosis before a PVI or DCCV using a readily available biomarker would minimise the risk for the patient and clinician alike. However, as far as now the quest to identify such a biomarker is still ongoing. D-dimer levels in the ADDIT-AF Study and identification of patients with LAA thrombus In their manuscript Almorad et al2 did compare two cut-offs of D-dimer to exclude LAA thrombus before DCCV. In their study patients did receive a transthoracic echocardiography 6 months before...
>> Read more

JACC

Heart Rhythm